Systems Biology Ireland

ucd.ie

SBI established in 2009 under the Science Foundation Ireland CSET programme has successfully developed an integrated mathematical modelling and experimental research programme focusing on the design of new therapeutic approaches to cancer, degenerative and inflammatory diseases based on a systems level, mechanistic understanding of cellular signal transduction networks. SBI is one of the few centres in Europe with the necessary in house expertise, technologies and capabilities to apply systems biology approaches to mammalian models. It’s recognition internationally within the field of systems biology led to the Centre’s invited participation in three large European funded consortia initiatives in 2012 namely the ITFoM, CASyM and ISBE, the last of which is included on the ESFRI 2010 Roadmap.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

news image

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More

Medical

LIGHT BIO PARTNERS WITH GINKGO BIOWORKS TO OPTIMIZE THE BRIGHTNESS OF GLOWING PLANTS THROUGH BIOLUMINESCENCE ENGINEERING

Light Bio | April 18, 2022

news image

Light Bio, Inc., a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to leverage Ginkgo's plant cell assays for bioluminescence engineering. Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants. The scientists at Light Bio have discovered a new...

Read More

Industrial Impact

ADM FURTHER EXPANDS MICROBIAL SCIENCE AND TECHNOLOGY INNOVATION CAPABILITIES WITH INVESTMENT IN PRECISION FERMENTATION LEADER ACIES BIO

ADM | October 22, 2021

news image

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re prope...

Read More

ACCESS BIOLOGICALS COMPLETES THE FIRST-EVER COMMERCIALLY AVAILABLE COVID-19 SEROCONVERSION PANEL TO CONFIRM SARS-COV-2 ANTIBODY ASSAYS

PR Newswire | September 07, 2020

news image

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

Read More
news image

Industrial Impact, Diagnostics

KITE AND ARCELLX CLOSE DEAL TO DEVELOP AND MARKET LATE-STAGE CLINICAL CART-DDBCMA

Kite Pharma and Arcellx | January 31, 2023

On January 30, 2023, Kite and Arcellx, Inc. informed that they have completed their previously-announced global strategic collaboration to co-develop and co-market CART-ddBCMA. CART-ddBCMA is Arcellx's lead late-stage candidate for treating patients with relapsed or refractory multiple myeloma. For the majority of patients, multiple myeloma is an incurable disease; hence, there is a continuing demand for treatments that are not only effective but also secure and e...

Read More
news image

Medical

LIGHT BIO PARTNERS WITH GINKGO BIOWORKS TO OPTIMIZE THE BRIGHTNESS OF GLOWING PLANTS THROUGH BIOLUMINESCENCE ENGINEERING

Light Bio | April 18, 2022

Light Bio, Inc., a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to leverage Ginkgo's plant cell assays for bioluminescence engineering. Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants. The scientists at Light Bio have discovered a new...

Read More
news image

Industrial Impact

ADM FURTHER EXPANDS MICROBIAL SCIENCE AND TECHNOLOGY INNOVATION CAPABILITIES WITH INVESTMENT IN PRECISION FERMENTATION LEADER ACIES BIO

ADM | October 22, 2021

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re prope...

Read More
news image

ACCESS BIOLOGICALS COMPLETES THE FIRST-EVER COMMERCIALLY AVAILABLE COVID-19 SEROCONVERSION PANEL TO CONFIRM SARS-COV-2 ANTIBODY ASSAYS

PR Newswire | September 07, 2020

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

Read More